SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Ultragenyx Announces the Completion of the Phase 1 Clinical Study of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease